Regeneron (REGN) Posts Positive Data on COVID-19 Antibody CocktailZacks Investment Research • 04/12/21
Regeneron says its COVID-19 antibody therapy cut risk of infection progressionMarket Watch • 04/12/21
Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV™ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19PRNewsWire • 04/12/21
Regeneron to request FDA clearance to use Covid antibody drug as a preventative treatmentCNBC • 04/12/21
Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV™ (casirivimab with imdevimab)PRNewsWire • 04/12/21
NIH recommends Lilly and Regeneron's combination antibody treatments to people with mild and moderate COVID-19Market Watch • 04/09/21
NIH COVID-19 Treatment Guidelines Strongly Recommend Use of REGEN-COV™ (casirivimab with imdevimab) in Outpatients at High Risk of Clinical ProgressionPRNewsWire • 04/09/21
Regeneron to Report First Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2021PRNewsWire • 04/06/21
Could Regeneron's Antibody Therapy Be as Important as Vaccines in Fighting COVID?The Motley Fool • 03/31/21
NIH-sponsored Trial Finds EYLEA® (aflibercept) Injection Reduced Vision-threatening Complications by 68% after Two Years in Diabetic Retinopathy PatientsPRNewsWire • 03/30/21
Regeneron's Covid-19 Antibody Could See Substantially Higher Sales This Year. Here's Why.Barrons • 03/24/21
Regeneron's President On COVID-19 Antibody Cocktail: 'Good News That Could Be Really Big News'Benzinga • 03/23/21
Regeneron's Lower Dose Of COVID-19 Antibody Cocktail Cuts Hospitalization, Death By 70%Benzinga • 03/23/21